Benefits
LDL cholesterol reduction (multiple RCTs)
Mycomeat trial (PMC10611638) crossover RCT in 20 healthy males found that 240 g/day mycoprotein for 14 days replacing red/processed meat REDUCED total cholesterol 6.74% (p=0.02) and LDL cholesterol 12.3% (p=0.02) vs baseline. Earlier Turnbull 1992 trial showed 26.9 g/day mycoprotein dry weight reduced plasma cholesterol 13% and LDL 9% vs control diet. Coelho 2019 systematic review identified 5 of 9 metabolic trials showing improved blood lipid profiles with mycoprotein. Mechanism: chitin/β-glucan fiber binding bile acids (similar to oat bran).
Muscle protein synthesis equivalent or superior to milk protein
Monteyne 2020 (PMID 32438401, AJCN) double-blind RCT in 20 resistance-trained young men compared 70 g mycoprotein (31.5 g protein, 2.5 g leucine) vs 31 g milk protein (26.2 g protein, leucine-matched 2.5 g) post-resistance exercise. RESULT: Mycoprotein stimulated MUSCLE PROTEIN SYNTHESIS to a GREATER EXTENT than milk protein in both rested and exercised muscle (despite leucine-matched comparison). Authors hypothesized fiber-derived prebiotic or non-leucine amino acid effects beyond leucine signaling alone.
Sustained satiety and weight management
Mycoprotein produces greater satiety than chicken or other animal protein in head-to-head meal trials. Williamson 2006 and Bottin 2016 RCTs showed mycoprotein meals reduced subsequent meal energy intake by 13-18% vs control meals. Combination of high protein, high fiber (~6 g/100 g cooked), and unique fungal cell wall structure produces prolonged satiety. Useful for weight management as meat substitute.
Postprandial glucose attenuation and insulin sensitivity
Mycoprotein reduces postprandial glucose response and may improve insulin sensitivity. Bottin 2016 (Br J Nutr) showed mycoprotein meal reduced 24-hour glucose AUC vs equivalent chicken meal in healthy and overweight individuals. Beta-glucan fiber from fungal cell wall slows carbohydrate absorption similarly to oat beta-glucan.
Sustainable environmental footprint
Mycoprotein production produces ~10x less CO2 emissions per kg protein than beef and ~2x less than chicken. Water footprint ~1/30 that of beef. Land use ~1/100 that of beef. Tuomisto 2022 Nature analysis identified mycoprotein as a key sustainable protein for climate change mitigation. Important for environmentally-conscious dietary choices alongside legitimate health benefits.
Mechanism of action
Bile acid sequestration and cholesterol reduction
Mycoprotein's fungal cell wall contains β-glucan (β-1,3/1,6, distinct from oat's β-1,3/1,4) and chitin — both viscous, fermentable fibers that bind bile acids in small intestine. Liver compensates by synthesizing more bile from cholesterol, depleting hepatic cholesterol pool. LDL receptor upregulation increases LDL clearance. Mechanism is similar to oat beta-glucan but with chitin contributing additional binding capacity.
Muscle protein synthesis via amino acid delivery
Mycoprotein provides complete amino acid profile (PDCAAS ~0.99 — comparable to milk and beef) with sufficient leucine to trigger anabolic signaling at doses ≥40 g protein. The Monteyne 2020 finding of MORE MPS than leucine-matched milk protein suggests possible additional effects beyond leucine — perhaps prebiotic/fiber-derived metabolites or unique fungal amino acid signaling not yet fully characterized.
Prebiotic/SCFA production from fungal fiber
Chitin and β-glucan from fungal cell walls are fermented by colonic bacteria producing short-chain fatty acids (acetate, propionate, butyrate). Increased Bifidobacteria and Faecalibacterium prausnitzii observed with mycoprotein consumption. May contribute to anti-inflammatory effects, gut health, and possibly indirect metabolic benefits.
Glycemic load reduction (viscous fiber gel)
β-glucan and chitin form viscous gel in stomach/small intestine, slowing gastric emptying and glucose diffusion. Reduces postprandial glucose excursion and may improve insulin sensitivity over time. Mechanism is identical to oat beta-glucan glucose effect.
Clinical trials
Randomized double-blind parallel-group trial (Monteyne AJ, Coelho MOC, Porter C, Abdelrahman DR, Jameson TSO, Jackman SR, Blackwell JR, Brook MS, Murton AJ, Alamdari N, Stephens FB, Wall BT 2020, Am J Clin Nutr 112(2):318-333, doi:10.1093/ajcn/nqaa092, PMID 32438401).
20 resistance-trained healthy young males (age 22 ± 1 y, BMI 25 ± 1) under primed continuous L-[ring-2H5]phenylalanine infusion. Ingested either 31 g milk protein (26.2 g protein, 2.5 g leucine) or 70 g mycoprotein (31.5 g protein, 2.5 g leucine — leucine-matched) following unilateral resistance exercise (contralateral leg as resting control).
Single bolus of mycoprotein stimulated resting AND post-exercise muscle protein synthesis to a GREATER extent than leucine-matched bolus of milk protein. Statistically significant superiority of mycoprotein vs milk protein in both rested and exercised muscle. Foundational evidence that mycoprotein is at least equivalent to and possibly superior to dairy protein for muscle anabolism — surprising given its lower leucine content per gram.
Comprehensive symposium review (Coelho MOC, Monteyne AJ, Dunlop MV, Harris HC, Morrison DJ, Stephens FB, Wall BT 2019, J Nutr 149(2):432S-440S, doi:10.1093/jn/nxy253, PMID 31187084).
Review of mycoprotein clinical literature — 13 human studies investigating health properties of mycoprotein.
Documented evidence of: (1) sustained satiety (multiple acute meal trials), (2) improved metabolic profiling — 5 of 9 trials found improved blood lipid levels, with cholesterol reductions 9-13% in meaningful intervention trials, (3) muscular protein synthetic response equivalent to milk/whey, (4) glucose and insulin control benefits, (5) low allergic reaction incidence. Concluded mycoprotein has substantial nutritional, health, and environmental benefits warranting incorporation into healthful diets.
Investigator-blind randomized crossover controlled trial (Farsi DN, Gallegos JL, Koutsidis G, Nelson A, Finnigan TJA, Cheung W, Munoz-Munoz JL, Bonham KW, Jhong J, Harvey DH, Commane DM 2023, Eur J Nutr 62(5):2169-2179, doi:10.1007/s00394-023-03110-2). PMC10611638.
20 metabolically healthy adult males consumed 240 g/day red and processed meat for 14 days followed by mycoprotein, OR vice versa (crossover design). Blood biochemical indices were a priori secondary endpoints.
Mycoprotein consumption REDUCED total cholesterol by 6.74% (p=0.02) and LDL cholesterol by 12.3% (p=0.02) from baseline. Triglycerides not significantly different (+0.19 mmol/L, p=0.09). Confirms cholesterol-lowering benefit of mycoprotein vs red/processed meat — important context as red/processed meat replacement is the most common real-world use case.
About this ingredient
Mycoprotein is a meat-substitute food made from the filamentous fungus Fusarium venenatum (initially misidentified as F. graminearum), discovered in the 1960s by Rank Hovis McDougall in soil samples from Marlow, England. Sold under the QUORN brand since 1985 (originally a partnership of RHM and ICI; now Quorn Foods Ltd, owned by Monde Nissin).
The fungus is grown in continuous fermentation tanks on glucose syrup with added ammonium and minerals — yielding mycelial filaments harvested at high density. Heat treatment, mixing with binders (typically egg albumen or potato starch), and texturing produce meat-like fibrous structure. Composition (per 100 g cooked Quorn-style mycoprotein, varies by product): ~14-15 g protein, ~5-6 g fiber, ~3 g fat, low saturated fat, no cholesterol, modest sodium.
PROTEIN PROFILE: complete essential amino acids; PDCAAS ~0.99 (comparable to milk, eggs, beef). Leucine content per gram of protein ~7.5% (vs whey ~10-12%) — explaining why larger doses are needed to match whey for muscle anabolism. UNIQUE COMPONENT: the fungal cell wall provides ~25% fiber as β-1,3/1,6-glucan and chitin — distinct from any plant or animal food.
This fiber profile drives the cholesterol-lowering and satiety benefits. EVIDENCE: 4/5 reflects: (1) MULTIPLE RCTs showing 8-13% LDL reduction (Mycomeat 2023, Turnbull 1992), (2) Monteyne 2020 PIVOTAL muscle protein synthesis trial showing mycoprotein > milk protein (PMID 32438401), (3) systematic review evidence (Coelho 2019 PMID 31187084) supporting satiety, metabolic, and protein-anabolic claims, (4) decades of safe consumer use across 17 countries, (5) clear mechanism (fungal fiber bile acid binding + complete protein). SAFETY: Excellent in widespread consumer use; rare allergic reactions documented but extremely uncommon.
Mold-allergic individuals should avoid. Best positioned as: (a) cholesterol management adjunct as red/processed meat replacement, (b) muscle building protein source equivalent to milk/whey at appropriate doses, (c) sustainable meat alternative for environmentally-conscious diets, (d) high-satiety food for weight management. The combination of efficacy across multiple endpoints (cholesterol + protein anabolism + satiety + sustainability) makes mycoprotein one of the more compelling 'alternative protein' options with substantial evidence base.